Browse studies

Find your next paid study

158 recruiting studies matching your filters

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximat…

C-Met Exon 14 Mutation

Estimated

~$10 – $8,750

Haihe Biopharma Co., Ltd.NCT04270591

The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to s…

LeukodystrophyWhite Matter DiseaseLeukoencephalopathies+63 more

Phase 1

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (…

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Estimated

~$10 – $7,500

NYU Langone HealthNCT05815173

Phase 2

Single-Arm Phase 2 Study of Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Eligible for Intensive Induction Chemotherapy

The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the…

Acute Myeloid LeukemiaIDH1 Mutation

Estimated

~$10 – $7,500

Justin Watts, MDNCT06782542

Phase 1

A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy …

Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more

Estimated

~$10 – $7,500

Richard Stone, MDNCT06313437

Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders

Rare genetic neurodevelopmental disorders, such as Syt-1 or Baker Gordon Syndrome (BAGOS) arise from mutations in genes essential for brain development and fun…

Baker Gordon SyndromeRare Neurodevelopmental ConditionsRare Neurogenetic Conditions+6 more

Estimated

~$10 – $750

University of Missouri-ColumbiaNCT07329257

Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targ…

Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more

Estimated

~$10 – $750

University of Colorado, DenverNCT03042221

Phase 2

A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy …

Cystic FibrosisCFTR Gene Mutation

Estimated

~$10 – $8,750

Arcturus Therapeutics, Inc.NCT06747858

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E …

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

Estimated

~$10 – $1,050

Novartis PharmaceuticalsNCT05868629

INTERogating Cancer for Etiology, Prevention and Therapy Navigation (INTERCEPTioN)

This study is being done to identify markers and causes of cancer by analyzing patient's DNA (i.e., genetic material), RNA, plasma, tissues, or other samples t…

CancerCancer Gene MutationPAN Gene Mutation+2 more

Estimated

~$10 – $750

Mayo ClinicNCT06008392

Observational

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

This is a single-armed screening research study which screens immediate family member of lung cancer patients with a driver mutation to see if lung cancer can …

Lung CancerDriver Mutation

Estimated

~$10 – $6,250

University of California, IrvineNCT07062172

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with k…

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo+1 more

Estimated

~$10 – $750

Vanderbilt University Medical CenterNCT05584722